289 related articles for article (PubMed ID: 28492153)
1. Prognostic Value of p53 Expression Intensity in Urothelial Cancers.
Qamar S; Inam QA; Ashraf S; Khan MS; Khokhar MA; Awan N
J Coll Physicians Surg Pak; 2017 Apr; 27(4):232-236. PubMed ID: 28492153
[TBL] [Abstract][Full Text] [Related]
2. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
[TBL] [Abstract][Full Text] [Related]
3. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
Koyuncuer A
Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
7. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma.
Halimi M; Salehi A; Baybordi H; Nezami N
Indian J Pathol Microbiol; 2009; 52(2):155-8. PubMed ID: 19332900
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.
Compérat E; Camparo P; Haus R; Chartier-Kastler E; Bart S; Delcourt A; Houlgatte A; François R; Capron F; Vieillefond A
Virchows Arch; 2006 Mar; 448(3):319-24. PubMed ID: 16283378
[TBL] [Abstract][Full Text] [Related]
10. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
11. Tissue Nuclear Matrix Protein Expression 22 in Various Grades and Stages of Bladder Cancer.
Mati Q; Qamar S; Ashraf S; Khokhar MA; Arshad U
J Coll Physicians Surg Pak; 2020 Dec; 30(12):1321-1325. PubMed ID: 33397061
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.
Wu CS; Pollack A; Czerniak B; Chyle V; Zagars GK; Dinney CP; Hu SX; Benedict WF
Urology; 1996 Mar; 47(3):305-10. PubMed ID: 8633392
[TBL] [Abstract][Full Text] [Related]
13. Prediction of lymph node metastasis based on p53 and nm23-H1 expression in muscle invasive grade III transitional cell carcinoma of bladder.
Park DS; Lee YT; Lee JM
Adv Exp Med Biol; 2003; 539(Pt A):67-85. PubMed ID: 15088897
[TBL] [Abstract][Full Text] [Related]
14. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder.
Khadim MT; Ahmed SA; Khan FA; Ikram A; Shaikh SY
J Pak Med Assoc; 2015 Aug; 65(8):851-6. PubMed ID: 26228330
[TBL] [Abstract][Full Text] [Related]
16. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
17. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
18. Further testing of morphometric grading in T(A,1) urothelial carcinomas of the urinary bladder and the additional value of p53 immunoquantitation.
Bol MG; Baak JP; Janssen EA; Breeuwsma NG; de Bruin PC
Anal Quant Cytol Histol; 2002 Apr; 24(2):114-20. PubMed ID: 12026049
[TBL] [Abstract][Full Text] [Related]
19. p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?
Steiner G; Bierhoff E; Schmidt D; Leissner J; Wolf HK; Albers P
Eur J Cancer; 2000 Mar; 36(5):610-4. PubMed ID: 10738125
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
